Biapenem
Chemical compound
- J01DH05 (WHO)
- In general: ℞ (Prescription only)
- (4R,5S,6S)-3-(6,7-dihydro-5H- pyrazolo[1,2-a] [1,2,4]triazol-8- ium-6-ylsulfanyl)- 6-(1-hydroxyethyl)- 4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2- ene-2-carboxylate
- 120410-24-4 Y
- 71339
- 64442 Y
- YR5U3L9ZH1
- CHEBI:3089 Y
- ChEMBL285347 Y
- DTXSID5046435
- Interactive image
- CC1C2C(C(=O)N2C(=C1SC3CN4C=NC=[N+]4C3)C(=O)[O-])C(C)O
InChI
- InChI=1S/C15H18N4O4S/c1-7-11-10(8(2)20)14(21)19(11)12(15(22)23)13(7)24-9-3-17-5-16-6-18(17)4-9/h5-11,20H,3-4H2,1-2H3/t7-,8-,10-,11-/m1/s1 Y
- Key:MRMBZHPJVKCOMA-YJFSRANCSA-N Y
Biapenem (INN) is a carbapenem antibiotic. It has in vitro activity against anaerobes.[1] 1-β-methyl-carbapenem antibiotic. Approved in Japan in 2001.
References
- ^ Aldridge KE, Morice N, Schiro DD (April 1994). "In vitro activity of biapenem (L-627), a new carbapenem, against anaerobes". Antimicrob. Agents Chemother. 38 (4): 889–93. doi:10.1128/aac.38.4.889. PMC 284564. PMID 8031067.
External links
- (in Japanese) Omegacin
- v
- t
- e
(inhibit synthesis
of peptidoglycan
layer of bacterial
cell wall by binding
to and inhibiting
PBPs, a group of
D-alanyl-D-alanine
transpeptidases)
Glycopeptides Lipoglycopeptides |
|
---|---|
Lipopeptides |
|
Polymyxins |
|
Other |
|
- Inhibit PG subunit synthesis and transport: NAM synthesis inhibition (Fosfomycin)
- DADAL/AR inhibitors (Cycloserine)
- bactoprenol inhibitors (Bacitracin)
- Hydrolyze NAM-NAG
- Tyrothricin
- Isoniazid#
- Teixobactin
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
This systemic antibiotic-related article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e